GROWTH-INHIBITION OF OVARIAN-CANCER CELLS INDUCED BY ANTISENSE IL-6 OLIGONUCLEOTIDES

被引:50
作者
WATSON, JM
BEREK, JS
MARTINEZMAZA, O
机构
[1] UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90024 USA
[2] UNIV CALIF LOS ANGELES, SCH MED,DEPT OBSTET & GYNECOL,DIV GYNECOL, GYNECOL ONCOL SERV, LOS ANGELES, CA 90024 USA
[3] JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA USA
关键词
D O I
10.1006/gyno.1993.1077
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In previous work, we saw that interleukin-6 (IL-6), a multifunctional cytokine, is produced by epithelial ovarian cancer cells and that ovarian cancer cells express the IL-6 receptor. Here, we examined the possibility that IL-6 acts as an autocrine growth factor for ovarian cancer cells. Inhibition of IL-6 gene expression by exposure to IL-6 antisense oligonucleotides resulted in greatly decreased cellular proliferation. Exposure of ovarian cancer cell lines (CAOV-3, OVCAR-3, and OC-436), to 1-5 μM of a 15-base single-stranded antisense IL-6 oligodeoxynucleotide, specific for a sequence in the second coding exon of the IL-6 gene, resulted in decreased IL-6 production and a >80-85% inhibition of cellular proliferation. However, the addition of exogenous IL-6 failed to restore the proliferation of the antisense-treated cells. Antibodies to IL-6 did not consistently inhibit cell growth nor did rIL-6 enhance precursor frequency in a limiting dilution analysis. These results suggest that IL-6 does not directly induce the proliferation of ovarian cancer cells although endogenous IL-6 production is needed for optimal cell growth. As the majority of epithelial ovarian cancers produce IL-6, the direct specific inhibition of IL-6 gene expression is of potential therapeutic value. © 1993 Academic Press, Inc.
引用
收藏
页码:8 / 15
页数:8
相关论文
共 25 条
[1]  
AKAZAWA K, 1983, CLIN CHIM ACTA, V131, P87
[2]   BIOLOGICAL AND CLINICAL ASPECTS OF INTERLEUKIN-6 [J].
HIRANO, T ;
AKIRA, S ;
TAGA, T ;
KISHIMOTO, T .
IMMUNOLOGY TODAY, 1990, 11 (12) :443-449
[3]  
KACINSKI BM, 1990, AM J PATHOL, V137, P135
[4]   AUTOCRINE GENERATION AND REQUIREMENT OF BSF-2/IL-6 FOR HUMAN MULTIPLE MYELOMAS [J].
KAWANO, M ;
HIRANO, T ;
MATSUDA, T ;
TAGA, T ;
HORII, Y ;
IWATO, K ;
ASAOKU, H ;
TANG, B ;
TANABE, O ;
TANAKA, H ;
KURAMOTO, A ;
KISHIMOTO, T .
NATURE, 1988, 332 (6159) :83-85
[5]   EXPRESSION OF A HEMATOPOIETIC GROWTH-FACTOR CDNA IN A FACTOR-DEPENDENT CELL-LINE RESULTS IN AUTONOMOUS GROWTH AND TUMORIGENICITY [J].
LANG, RA ;
METCALF, D ;
GOUGH, NM ;
DUNN, AR ;
GONDA, TJ .
CELL, 1985, 43 (02) :531-542
[6]  
LI BY, 1992, CANCER RES, V52, P2248
[7]   EPITHELIAL OVARIAN-CANCER - A CYTOKINE PROPELLED DISEASE [J].
MALIK, S ;
BALKWILL, F .
BRITISH JOURNAL OF CANCER, 1991, 64 (04) :617-620
[8]   INTERLEUKIN-6 (IL-6) FUNCTIONS AS AN INVITRO AUTOCRINE GROWTH-FACTOR IN RENAL-CELL CARCINOMAS [J].
MIKI, S ;
IWANO, M ;
MIKI, Y ;
YAMAMOTO, M ;
TANG, B ;
YOKOKAWA, K ;
SONODA, T ;
HIRANO, T ;
KISHIMOTO, T .
FEBS LETTERS, 1989, 250 (02) :607-610
[9]   AIDS KAPOSI SARCOMA-DERIVED CELLS PRODUCE AND RESPOND TO INTERLEUKIN-6 [J].
MILES, SA ;
REZAI, AR ;
SALAZARGONZALEZ, JF ;
VANDERMEYDEN, M ;
STEVENS, RH ;
LOGAN, DM ;
MITSUYASU, RT ;
TAGA, T ;
HIRANO, T ;
KISHIMOTO, T ;
MARTINEZMAZA, O .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (11) :4068-4072